Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction
Titel:
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction
Auteur:
Gibson, C. Michael Kastelein, John J.P. Phillips, Adam T. Aylward, Philip E. Yee, Megan K. Tendera, Michal Nicholls, Stephen J. Pocock, Stuart Goodman, Shaun G. Alexander, John H. Lincoff, A. Michael Bode, Christoph Duffy, Danielle Heise, Mark Berman, Gail Mears, Sojaita Jenny Tricoci, Pierluigi Deckelbaum, Lawrence I. Steg, P. Gabriel Ridker, Paul Mehran, Roxana